Publicacións en colaboración con investigadores/as de Charles University in Prague (65)

2024

  1. Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

    The Journal of rheumatology, Vol. 51, Núm. 4, pp. 378-389

2023

  1. A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 9, pp. 2497-2509

  2. Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry

    The European respiratory journal

  3. Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry (Respiratory Research, (2022), 23, 1, (352), 10.1186/s12931-022-02275-4)

    Respiratory Research

  4. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment

    Journal of Rheumatology, Vol. 50, Núm. 8, pp. 1009-1019

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

    Pharmacopsychiatry, Vol. 55, Núm. 2, pp. 73-86

  3. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

    Respiratory Research, Vol. 23, Núm. 1

  4. Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study

    Intensive Care Medicine, Vol. 48, Núm. 6, pp. 690-705

  5. Correction to: Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITE-COVID study (Intensive Care Medicine, (2022), 48, 6, (690-705), 10.1007/s00134-022-06705-1)

    Intensive Care Medicine

  6. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366

  7. Erratum: Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels (Pharmacopsychiatry (2022) 55 2 (73-86))

    Pharmacopsychiatry

  8. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response

    Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807

  9. Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

    Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218

  10. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 6, pp. 1140-1151

  11. Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy

    Scientific Reports, Vol. 12, Núm. 1

  12. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751

2021

  1. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis

    Nephrology Dialysis Transplantation, Vol. 36, Núm. 12, pp. 2308-2320

  2. Cystathionine ß-synthase deficiency in the E-HOD registry-part I: pyridoxine responsiveness as a determinant of biochemical and clinical phenotype at diagnosis

    Journal of Inherited Metabolic Disease, Vol. 44, Núm. 3, pp. 677-692

  3. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 11, pp. 1410-1418